Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials.

Decreased activity of the enzyme paraoxonase-1 (PON1) has been demonstrated in cardiovascular diseases. Statins, the forefront of pharmacotherapy for dyslipidemia, have been shown to enhance PON1 activity but clinical findings have not been conclusive.